Condition

Stage IIIC Colorectal Cancer AJCC v8

ClinicalTrials.gov condition label

Clinical trials8

Recruiting1

Common interventions13

Lead sponsors shown6

Clinical trials

8 shown

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsNCT04771520 · 2021-01-20

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer SurvivorsNCT07259304 · 2021-11-24

ACTIVE_NOT_RECRUITING

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal CancerNCT04428905 · 2020-07-11

ACTIVE_NOT_RECRUITING

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesNCT04501913 · 2019-12-24

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyNCT03707574 · 2019-07-16

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerNCT04067960 · 2019-06-06

Patient Portal and Navigation Program in Providing Information for Asian American Cancer PatientsNCT03867916 · 2018-12-13

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerNCT02983578 · 2017-03-02

ACTIVE_NOT_RECRUITING

Common interventions

Quality-of-Life AssessmentOTHER4 Questionnaire AdministrationOTHER3 Biospecimen CollectionPROCEDURE2 Survey AdministrationOTHER2 AvapritinibDRUG1 DanvatirsenDRUG1 DurvalumabBIOLOGICAL1 Genetic TestingOTHER1 Medical Device Usage and EvaluationOTHER1 Patient MonitoringPROCEDURE1 Patient Navigation ProgramBEHAVIORAL1 Survivorship Care PlanOTHER1 TelemedicineOTHER1

Leading sponsors

City of Hope Medical Center2 M.D. Anderson Cancer Center2 Mayo Clinic1 National Cancer Institute (NCI)1 University of California, San Francisco1 University of Southern California1

Trial status mix

COMPLETED4

ACTIVE_NOT_RECRUITING3

RECRUITING1

Phase mix

PHASE22

EARLY_PHASE11

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.